| dc.contributor.author | KÜRTÜNCÜ, Murat | |
| dc.date.accessioned | 2022-02-18T10:24:30Z | |
| dc.date.available | 2022-02-18T10:24:30Z | |
| dc.identifier.citation | KÜRTÜNCÜ M., "Natalizumab Treatment in Multiple Sclerosis", NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.48, ss.56-60, 2011 | |
| dc.identifier.issn | 1300-0667 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_997f28a2-7bf5-4272-a752-e779486633f6 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/179186 | |
| dc.identifier.uri | https://doi.org/10.4274/npa.y6430 | |
| dc.description.abstract | Natalizumab is the first monoclonal antibody approved for the treatment of multiple sclerosis. It is an alpha 4-integrin antagonist that inhibits transmigration of peripheral lymphocytes through the blood-brain barrier. Natalizumab is recommended only for patients who continue to worsen under interferon or glatiramer acetate treatment or who do not tolerate those treatments. Since this drug might occasionally lead to opportunistic infections such as PML, clinicians should always consider the risk-benefit ratio when they decide to use this treatment. (Archives of Neuropsychiatry 2011:48 Supplement 2:56-60) | |
| dc.language.iso | eng | |
| dc.subject | Neurology | |
| dc.subject | Neurology (clinical) | |
| dc.subject | Life Sciences | |
| dc.subject | Health Sciences | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Nöroloji | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | KLİNİK NEUROLOJİ | |
| dc.title | Natalizumab Treatment in Multiple Sclerosis | |
| dc.type | Makale | |
| dc.relation.journal | NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 48 | |
| dc.identifier.startpage | 56 | |
| dc.identifier.endpage | 60 | |
| dc.contributor.firstauthorID | 3379200 | |
